ES
84
2
PAYX
21
-2
SLG
13
-4
CF
38
2
CMG
43
-2
INTU
43
2
CRM
22
-3
VZ
47
5
DVN
54
4
SIG
75
-7
MTB
59
-5
ROK
60
-2
NWL
43
-11
NKE
40
-5
PG
43
5
FLS
53
-2
UNH
32
2
FSLR
40
3
MET
32
-11
AMG
66
-3
ES
84
2
PAYX
21
-2
SLG
13
-4
CF
38
2
CMG
43
-2
INTU
43
2
CRM
22
-3
VZ
47
5
DVN
54
4
SIG
75
-7
MTB
59
-5
ROK
60
-2
NWL
43
-11
NKE
40
-5
PG
43
5
FLS
53
-2
UNH
32
2
FSLR
40
3
MET
32
-11
AMG
66
-3
Financhill
Back

Soleno Therapeutics, Inc. 10K Form

Sell
43

SLNO
Soleno Therapeutics, Inc.

Last Price:
$39.05
Seasonality Move:
17.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SLNO News And Ratings

See the #1 stock for the next 7 days that we like better than SLNO

SLNO Financial Statistics

Sales & Book Value

Annual Sales: $190.4M
Cash Flow: $48.6M
Price / Cash Flow: 43.1
Annual Sales: $8.61
Price / Book: 4.66

Profitability

EPS (TTM): 0.22280
Net Income (TTM): $20.5M
Gross Margin: $187.7M
Return on Equity: 6.16%
Return on Assets: 4.77%

Soleno Therapeutics, Inc. Earnings Forecast

Key Soleno Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 14 years for SLNO is 98.58%.
  • The Selling, General & Administrative Expenses for SLNO have been equal to 69.39% of Gross Profit Margin.
  • The Research & Development expenses have been 21.34% of Revenue.
  • The Interest Expense is 26.74% of Operating Income.
  • The Net Earning history of SLNO is 10.75% of Total Revenues.
  • Per Share Earnings over the last 14 years have been positive in 9 years.

Soleno Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SLNO
CUSIP: 834203
Website: soleno.life

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 5.8
Quick Ratio: 5.44

Price-to-Earnings

Trailing P/E Ratio: 99.95
Forward P/E Ratio: 18.32

SLNO Technical Analysis vs Fundamental Analysis

Sell
43
Soleno Therapeutics, Inc. (SLNO) is a Sell

Is Soleno Therapeutics, Inc. a Buy or a Sell?